{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:54:11Z","timestamp":1764276851007,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2495-5","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T04:40:12Z","timestamp":1496378412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-8637","authenticated-orcid":false,"given":"Khalid","family":"Eljaaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Aljabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayar","family":"Al Mohajer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Nix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"issue":"Suppl 2","key":"2495_CR1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27\u201372.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"2495_CR2","first-page":"1","volume":"64","author":"WS Lim","year":"2009","unstructured":"Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2009;64(Suppl 3):1\u201355.","journal-title":"Thorax"},{"issue":"6","key":"2495_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03602.x","volume":"17","author":"M Woodhead","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011;17(6):1\u201324.","journal-title":"Clin Microbiol Infect"},{"key":"2495_CR4","unstructured":"National Institute for Health and Care Excellence. Diagnosis and management of community- and hospital-acquired pneumonia in adults. Published 3 Dec 2014. Available at: \nhttps:\/\/www.nice.org.uk\/guidance\/cg191\n\n. Accessed 25 May 2016."},{"key":"2495_CR5","first-page":"CD004418","volume":"9","author":"N Eliakim-Raz","year":"2012","unstructured":"Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst rev. 2012;9:CD004418.","journal-title":"Cochrane Database Syst rev"},{"issue":"7489","key":"2495_CR6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/bmj.38334.591586.82","volume":"330","author":"GD Mills","year":"2005","unstructured":"Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005;330(7489):456.","journal-title":"BMJ"},{"issue":"17","key":"2495_CR7","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/archinte.165.17.1992","volume":"165","author":"D Shefet","year":"2005","unstructured":"Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med. 2005;165(17):1992\u20132000.","journal-title":"Arch Intern Med"},{"issue":"6","key":"2495_CR8","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dku033","volume":"69","author":"W Nie","year":"2014","unstructured":"Nie W, Li B, Xiu Q. \u03b2-Lactam\/macrolide dual therapy versus \u03b2-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(6):1441\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2495_CR9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/resp.12835","volume":"21","author":"N Horita","year":"2016","unstructured":"Horita N, Otsuka T, Haranaga S, et al. Beta-Lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. Respirology. 2016;21(7):1193\u2013200.","journal-title":"Respirology"},{"key":"2495_CR10","unstructured":"Higgins JPT, Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies In: Higgins JPT, Green S eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration, 2011. Available at: \nhttp:\/\/www.cochrane-handbook.org\n\n. Accessed 8 June 2016."},{"issue":"8","key":"2495_CR11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.rmed.2004.04.007","volume":"98","author":"P Leophonte","year":"2004","unstructured":"Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med. 2004;98(8):708\u201320.","journal-title":"Respir Med"},{"issue":"1","key":"2495_CR12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.119.1.185","volume":"119","author":"P Petitpretz","year":"2001","unstructured":"Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. CAP5 Moxifloxacin study group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest. 2001;119(1):185\u201395.","journal-title":"Chest"},{"issue":"4","key":"2495_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/00365549850160710","volume":"30","author":"SR Norrby","year":"1998","unstructured":"Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998;30(4):397\u2013404.","journal-title":"Scand J Infect Dis"},{"issue":"12","key":"2495_CR14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","volume":"174","author":"N Garin","year":"2014","unstructured":"Garin N, Genn\u00e9 D, Carballo S, et al. \u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174(12):1894\u2013901.","journal-title":"JAMA Intern Med"},{"issue":"15","key":"2495_CR15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0025-7753(00)71625-3","volume":"115","author":"V Kalbermatter","year":"2000","unstructured":"Kalbermatter V, Bagilet D, Diab M, Javkin E. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin\/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization. Medicina Clinica. 2000;115(15):561\u20133.","journal-title":"Medicina Clinica"},{"key":"2495_CR16","first-page":"32","volume":"59","author":"S Kohno","year":"2011","unstructured":"Kohno S, Watanabe A, Aoki N, et al. Clinical phase III comparative study of intravenous levofloxacin and ceftriaxone in community-acquired pneumonia treatment. J. Chemother. 2011;59:32\u201345.","journal-title":"J. Chemother"},{"key":"2495_CR17","volume-title":"Community-acquired bacterial pneumonia: developing drugs for treatment","author":"Guidance for Industry","year":"2014","unstructured":"Guidance for Industry. Community-acquired bacterial pneumonia: developing drugs for treatment. Rockville: US Department of Health and Human Services, Food and Drug Administration; 2014."},{"issue":"14","key":"2495_CR18","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","volume":"372","author":"DF Postma","year":"2015","unstructured":"Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312\u201323.","journal-title":"N Engl J Med"},{"key":"2495_CR19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","volume":"2","author":"NS Zhong","year":"2015","unstructured":"Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015;2:161\u201371.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"2495_CR20","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","volume":"51","author":"TM File Jr","year":"2010","unstructured":"File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395\u2013405.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2495_CR21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/civ1214","volume":"62","author":"NJ Gadsby","year":"2016","unstructured":"Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62(7):817\u201323.","journal-title":"Clin Infect Dis"},{"key":"2495_CR22","unstructured":"World Health Organization. Legionellosis. Published June 2016. Available at: \nhttp:\/\/www.who.int\/mediacentre\/factsheets\/fs285\/en\/\n\n. Accessed 3 Aug 2016."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2495-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T04:40:25Z","timestamp":1496378425000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2495-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2495"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2495-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2017,6,2]]},"article-number":"385"}}